Objectives: Determination of the sustained virologic response in chronic HCV infected patients with HCV related nephropathy receiving direct acting antiviral drugs and assessment of the immunological, clinical and renal responses to DAAs in this group of patients.
Methods: This prospective observational study was carried out over a period of two years and included 34 patients diagnosed with HCV nephropathy for whom virological, immunological, clinical and renal responses were assessed pre and 12 weeks post treatment who were planned to be treated with DAAs (in the form of combination of OBV- PTV/r with RBV, combination of SOF/SIM, or combination of SOF/DCV with or without RBV according to the availability).
Results: Thirty- four HCV nephropathy patients were observed while receiving DAAs and for 12 weeks after. Renal biopsy was done in thirty patients while four refused. The mean age of patients was 53.1 ± 10.1 years and 55.9% of them were males. Membranoproliferative lesion was detected in 83% of biopsied cases. Sustained virological response 12 weeks after treatment detected in 97%. The median eGFR and proteinuria were improved after treatment , However, Partial and complete improvement of eGFR and proteinuria was detected in 57% and 44% of patients, respectively. Clinical response of other extra renal manifestations and immunological response either complete or partial were detected in 59% and 47% respectively.

Background:The ability of extrarenal tissues to convert 25- hydroxyvitamin D [25(OH)D] into 1,25-hydroxyvitamin D [1,25(OH)2D] and its dependence on substrate levels provide the rationale for supplementing vitamin D in dialysis patients who usually have severe depletion of both: calcitriol and vitamin D.
The primary aim of the study was to detect serum Vit d3 levels in cohort of Egyptian Hemodialysis patients and to check the effect of its replacement on serum levels .serum1,25(OH)2D in hemodialysis patients with vitamin D deficiency. Secondary outcomes were changes in serum calcium, phosphate, parathyroid hormone (PTH).
Patients and Methods: 40 patients (25 males and 15 females) with Chronic Kidney Disease CKD (stage V) on regular heamodialysis, attending at Nephrology unit, Internal medicine department, Mansoura University Hospital during the period from January to June 2020. Another 40 persons- Age and sex matched- was selected randomly from the medical workers and served as control group .According to laboratory investigation and clinical examination deficient patients treated with Devarol-S (cholecalciferol) for 3 months and then revaluated. Deficient patients received 50000 IU monthly for 3 Consecutive months.
Results: The study was carried on 80 persons, 27 male patients ( 73.0%) and 13 female patients (27.0% ). Their mean age was (47.16±14.92) years .The mean dialysis duration is (4.68±2.42) years and 40 person as control group.